Coherus BioSciences, Inc. NASDAQ:CHRS

Coherus BioSciences stock price today

$1.07
-0.41
-28.19%
Financial Health
0
1
2
3
4
5
6
7
8
9

Coherus BioSciences stock price monthly change

-10.24%
month

Coherus BioSciences stock price quarterly change

-10.24%
quarter

Coherus BioSciences stock price yearly change

-44.61%
year

Coherus BioSciences key metrics

Market Cap
165.90M
Enterprise value
1.02B
P/E
-2.03
EV/Sales
4.85
EV/EBITDA
-4.01
Price/Sales
2.88
Price/Book
-4.42
PEG ratio
-1.54
EPS
-0.7
Revenue
301.87M
EBITDA
-165.56M
Income
-59.28M
Revenue Q/Q
137.58%
Revenue Y/Y
64.63%
Profit margin
-138.24%
Oper. margin
-121.72%
Gross margin
66.79%
EBIT margin
-121.72%
EBITDA margin
-54.85%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Coherus BioSciences stock price history

Coherus BioSciences stock forecast

Coherus BioSciences financial statements

Average Price Target
Last Year

$6

Potential upside: 460.74%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Coherus BioSciences, Inc. (NASDAQ:CHRS): Profit margin
Jun 2023 58.71M -42.86M -73.01%
Sep 2023 74.56M -39.64M -53.16%
Dec 2023 91.52M -79.65M -87.03%
Mar 2024 77.06M 102.87M 133.49%
Coherus BioSciences, Inc. (NASDAQ:CHRS): Debt to assets
Jun 2023 469591000 644.35M 137.22%
Sep 2023 583783000 717.38M 122.89%
Dec 2023 629604000 823.02M 130.72%
Mar 2024 763545000 845.38M 110.72%
Coherus BioSciences, Inc. (NASDAQ:CHRS): Cash Flow
Jun 2023 -38.91M 41.36M 54.32M
Sep 2023 -54.3M 50.54M 11.10M
Dec 2023 -12.93M 35.20M 366K
Mar 2024 -46.76M 202.76M 887K

Coherus BioSciences alternative data

Coherus BioSciences, Inc. (NASDAQ:CHRS): Employee count
Aug 2023 307
Sep 2023 294
Oct 2023 294
Nov 2023 294
Dec 2023 299
Jan 2024 299
Feb 2024 299
Mar 2024 306
Apr 2024 306
May 2024 306
Jun 2024 249
Jul 2024 249

Coherus BioSciences other data

100.00% 0.00%
of CHRS is owned by hedge funds
115.14M -848.92K
shares is hold by hedge funds

Coherus BioSciences, Inc. (NASDAQ:CHRS): Insider trades (number of shares)
Period Buy Sel
Nov 2023 0 223100
Transaction Date Insider Security Shares Price per share Total value Source
Option
LANFEAR DENNIS M director, officer.. Common Stock 258,940 $1.42 $366,918
Sale
LANFEAR DENNIS M director, officer.. Common Stock 223,100 $2.02 $449,770
Option
LANFEAR DENNIS M director, officer.. Common Stock 41,000 $1.42 $58,097
Option
LANFEAR DENNIS M director, officer.. Stock Option (Right to Buy) 299,940 $1.42 $425,015
Option
WAHLSTROM MATS director
Stock Option (Right to Buy) 29,994 $2.08 $62,507
Sale
STILWELL MCDAVID officer: Chief Financial Officer
Common Stock 3,507 $16.8 $58,918
Sale
HEALY JAMES director
Common Stock, $0.0001 par value 286,076 $16.12 $4,611,545
Sale
HEALY JAMES director
Common Stock, $0.0001 par value 48,329 $17.17 $829,809
Sale
HEALY JAMES director
Common Stock, $0.0001 par value 100,150 $18.06 $1,808,709
Purchase
STILWELL MCDAVID
Common Stock 3,700 $13.42 $49,669
Patent
Grant
Filling date: 25 Jun 2020 Issue date: 2 Aug 2022
Grant
Filling date: 9 Sep 2019 Issue date: 26 Jul 2022
Application
Filling date: 26 May 2020 Issue date: 30 Jun 2022
Application
Filling date: 1 May 2020 Issue date: 23 Jun 2022
Application
Filling date: 27 Dec 2019 Issue date: 23 Jun 2022
Application
Filling date: 27 Dec 2019 Issue date: 23 Jun 2022
Application
Filling date: 27 Dec 2019 Issue date: 12 May 2022
Grant
Filling date: 3 Apr 2018 Issue date: 22 Feb 2022
Application
Filling date: 17 Jun 2021 Issue date: 10 Feb 2022
Grant
Filling date: 28 Oct 2016 Issue date: 25 Jan 2022
Wednesday, 18 December 2024
globenewswire.com
Monday, 16 December 2024
seekingalpha.com
Tuesday, 3 December 2024
benzinga.com
Wednesday, 27 November 2024
globenewswire.com
Wednesday, 6 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
Friday, 9 August 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
Thursday, 1 August 2024
globenewswire.com
Thursday, 27 June 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Thursday, 23 May 2024
globenewswire.com
globenewswire.com
Friday, 10 May 2024
Seeking Alpha
Thursday, 9 May 2024
Zacks Investment Research
Wednesday, 1 May 2024
GlobeNewsWire
Wednesday, 20 March 2024
Seeking Alpha
Thursday, 14 March 2024
The Motley Fool
Wednesday, 13 March 2024
Seeking Alpha
Tuesday, 6 February 2024
The Motley Fool
Tuesday, 23 January 2024
The Motley Fool
Monday, 22 January 2024
The Motley Fool
InvestorPlace
Wednesday, 3 January 2024
GlobeNewsWire
Thursday, 28 December 2023
The Motley Fool
Zacks Investment Research
Wednesday, 27 December 2023
Proactive Investors
Market Watch
  • What's the price of Coherus BioSciences stock today?

    One share of Coherus BioSciences stock can currently be purchased for approximately $1.07.

  • When is Coherus BioSciences's next earnings date?

    Unfortunately, Coherus BioSciences's (CHRS) next earnings date is currently unknown.

  • Does Coherus BioSciences pay dividends?

    No, Coherus BioSciences does not pay dividends.

  • How much money does Coherus BioSciences make?

    Coherus BioSciences has a market capitalization of 165.90M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.89% to 257.24M US dollars.

  • What is Coherus BioSciences's stock symbol?

    Coherus BioSciences, Inc. is traded on the NASDAQ under the ticker symbol "CHRS".

  • What is Coherus BioSciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Coherus BioSciences?

    Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Coherus BioSciences's key executives?

    Coherus BioSciences's management team includes the following people:

    • Mr. Dennis M. Lanfear Chairman, Pres & Chief Executive Officer(age: 70, pay: $1,820,000)
    • Mr. Vladimir Vexler Chief Scientific Officer(age: 67, pay: $768,470)
  • How many employees does Coherus BioSciences have?

    As Jul 2024, Coherus BioSciences employs 249 workers, which is 19% less then previous quarter.

  • When Coherus BioSciences went public?

    Coherus BioSciences, Inc. is publicly traded company for more then 10 years since IPO on 6 Nov 2014.

  • What is Coherus BioSciences's official website?

    The official website for Coherus BioSciences is coherus.com.

  • Where are Coherus BioSciences's headquarters?

    Coherus BioSciences is headquartered at 333 Twin Dolphin Drive, Redwood City, CA.

  • How can i contact Coherus BioSciences?

    Coherus BioSciences's mailing address is 333 Twin Dolphin Drive, Redwood City, CA and company can be reached via phone at +65 06493530.

  • What is Coherus BioSciences stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Coherus BioSciences in the last 12 months, the avarage price target is $6. The average price target represents a 460.74% change from the last price of $1.07.

Coherus BioSciences company profile:

Coherus BioSciences, Inc.

coherus.com
Exchange:

NASDAQ

Full time employees:

235

Industry:

Biotechnology

Sector:

Healthcare

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

333 Twin Dolphin Drive
Redwood City, CA 94065

CIK: 0001512762
ISIN: US19249H1032
CUSIP: 19249H103